New insights into stage and prognosis in small cell lung cancer: an analysis of 968 cases

Dayen, C.; Debieuvre, D.; Molinier, Olivier; Raffy, O.; Paganin, F.; Virally, J.; Larivé, Sébastien; Desurmont-Salasc, Béatrice; Perrichon, M.; Fortin, Martin; Grivaux, M

doi:10.21037/jtd.2017.11.52

Cited by 28 publications

(27 citation statements)

References 28 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Stage was the most frequently investigated clinical parameter in addition to TLG. TLG had an additional or superior prognostic value to stage for OS [ 23 , 32 , 33 , 35 ], but the results applied only for one subgroup in the study of Nobashi et al [ 1 ]. Other clinical parameters were sporadic included in the multivariate analysis ( Figure 3 c).…”

Section: Resultsmentioning

confidence: 99%

“…Compared with other covariates included in the multivariate analysis, an additional independent or superior prognostic value of SU-Vmax to stage, age, blood lactate dehydrogenase (LDH), sex, and performance status (PS) was sporadic (Figure 3a). 1 Özdemir accounted twice due to different results in subgroups, 2 Nobashi accounted twice due to different results in subgroups, 3 Choi accounted twice due to different results in subgroups.…”

Section: Baseline Suvmentioning

confidence: 99%

“…Small cell lung cancer (SCLC) is an aggressive cancer, and most patients present at an advanced stage [ 1 ]. Treatment options are limited.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Prognostic Value of 18F–FDG–PET Parameters in Patients with Small Cell Lung Cancer: A Meta-Analysis and Review of Current Literature

et al. 2021

View full text Add to dashboard Cite

Many studies have suggested a prognostic value of one or several positron emission tomography (PET) parameters in patients with small cell lung cancer (SCLC). However, studies are often small, and there is a considerable interstudy disagreement about which PET parameters have a prognostic value. The objective of this study was to perform a review and meta-analysis to identify the most promising PET parameter for prognostication. PubMed®, Cochrane, and Embase® were searched for papers addressing the prognostic value of any PET parameter at any treatment phase with any endpoint in patients with SCLC. Pooled hazard ratios (HRs) were calculated by a random effects model for the prognostic value of the baseline maximum standardized uptake value (SUVmax) and metabolic tumor volume (MTV). The qualitative analysis included 38 studies, of these, 19 studies were included in the meta-analyses. The pooled results showed that high baseline MTV was prognostic for overall survival (OS) (HR: 2.83 (95% confidence interval [CI]: 2.00–4.01) and progression-free survival (PFS) (HR: 3.11 (95% CI: 1.99–4.90)). The prognostic value of SUVmax was less pronounced (OS: HR: 1.50 (95% CI: 1.17–1.91); PFS: HR: 1.24 (95% CI: 0.94–1.63)). Baseline MTV is a strong prognosticator for OS and PFS in patients with SCLC. MTV has a prognostic value superior to those of other PET parameters, but whether MTV is superior to other prognosticators of tumor burden needs further investigation.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Baseline Suvmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic Value of 18F–FDG–PET Parameters in Patients with Small Cell Lung Cancer: A Meta-Analysis and Review of Current Literature

et al. 2021

View full text Add to dashboard Cite

show abstract

“…As novel diagnostic modalities such as CT, MRI, and PET-CT have been increasingly adopted into clinical practice, the sensitivity of detecting small lesions has improved in parallel. 24 In the current study, the initial comprehensive staging according to the 8th TNM classification including PET-CT and brain MRI/CT had enough power to accurately discriminate between the subgroups of ED-SCLC patients treated with chemotherapy.…”

Section: Discussionmentioning

confidence: 62%

Prognostic significance of the 8th edition of the TNM classification for patients with extensive disease small cell lung cancer

Shirasawa¹,

Fukui²,

Kusuhara³

et al. 2018

CMAR

View full text Add to dashboard Cite

BackgroundSmall cell lung cancer (SCLC) is typically categorized according to disease extent as limited or extensive, and utility of the 8th TNM classification, recommended for lung cancer staging, which demonstrates a strong association with non-small-cell lung cancer (NSCLC) management, remains unclear.MethodsThis retrospective study included 277 consecutive SCLC patients treated at a single institution between 2008 and 2016.ResultsAccording to the currently used two-stage system, 186 (65.7%) of the patients were classified as having extensive disease (ED)-SCLC. Among the ED-SCLC patients, ten (5.3%), 38 (20.4%), 32 (17.2%), and 106 (57.0%) were categorized into stages M0, M1a, M1b, and M1c, respectively, according to the 8th TNM classification. There was a significant difference in overall survival based on the M descriptors: 15.8 (95% CI 9.4–22.2) months in the M1b group vs 7.3 (95% CI 5.7–8.9) months in the M1c group (P<0.001). Multivariate analysis showed that in addition to the known prognostic factors such as performance status, serum albumin, and lactate dehydrogenase, M descriptor was a prognostic factor (HR 1.95, 95% CI 1.38–2.77; P<0.001).ConclusionThe 8th TNM classification has a prognostic value in SCLC. Similarly to NSCLC, treatment approaches should be considered on the basis of the 8th TNM classification, especially stage IVA separate from stage IVB in ED-SCLC patients.

show abstract

“…Unfortunately, almost all patients relapse with chemoresistant disease (6) and there has been almost no improvement in 1-year SCLC mortality rate over 10 years (7).…”

Section: Introductionmentioning

confidence: 99%

Beneficial effect of additional treatment with�widely�available anticancer agents in advanced small�lung cell carcinoma: A case report

Kruk¹

2018

mol clin onc

View full text Add to dashboard Cite

Small-cell lung carcinoma is a type of lung cancer characterized by very poor prognosis, as the majority of the patients have already developed metastases at initial diagnosis. Small-cell lung cancer accounts for ~15% of all lung cancer cases. The present study reports the case of a female patient with advanced-stage small-cell lung cancer. The patient received the standard treatments (6 cycles of platinum and etoposide chemotherapy followed by Gamma Knife treatment of suspicious mediastinal lymphnodes); in addition, naturally derived agents (curcumin, parthenolide, betuline, sulforaphane, withanolides, lactoferrin, pomegranate fruit extract, flaxseed and dioscorea) were alternately administered at increased doses, while previously prescribed medications for other comorbidities (metformin and atorvastatin) were continued. Complete regression of the tumour was observed, and the patient remains in full remission and cancer-free for >7 years. Moreover, no treatment-related side effects and no drug interactions were observed.

show abstract

New insights into stage and prognosis in small cell lung cancer: an analysis of 968 cases

Cited by 28 publications

References 28 publications

Prognostic Value of 18F–FDG–PET Parameters in Patients with Small Cell Lung Cancer: A Meta-Analysis and Review of Current Literature

Prognostic Value of 18F–FDG–PET Parameters in Patients with Small Cell Lung Cancer: A Meta-Analysis and Review of Current Literature

Prognostic significance of the 8th edition of the TNM classification for patients with extensive disease small cell lung cancer

Beneficial effect of additional treatment with�widely�available anticancer agents in advanced small�lung cell carcinoma: A case report

Contact Info

Product

Resources

About